The mGluR 2/3 agonist LY379268 reverses NMDA receptor antagonist effects on cortical gamma oscillations and phase coherence,but not working memory impairments,in mice
Restricted accessResearch articleFirst published online December, 2019
The mGluR 2/3 agonist LY379268 reverses NMDA receptor antagonist effects on cortical gamma oscillations and phase coherence,but not working memory impairments,in mice
Abnormalities in neural oscillations that occur in the gamma frequency range (30–80 Hz) may underlie cognitive deficits in schizophrenia. Both cognitive impairments and gamma oscillatory disturbances can be induced in healthy people and rodents by administration of N-methyl-D-aspartate receptor (NMDAr) antagonists.
Aims:
We studied relationships between cognitive impairment and gamma abnormalities following NMDAr antagonism, and attempted to reverse deficits with the metabotropic glutamate receptor type 2/3 (mGluR2/3) agonist LY379268.
Methods:
C57/Bl6 mice were trained to perform the Trial-Unique Nonmatching to Location (TUNL) touchscreen test for working memory. They were then implanted with local field potential (LFP) recording electrodes in prefrontal cortex and dorsal hippocampus. Mice were administered either LY379268 (3 mg/kg) or vehicle followed by the NMDAr antagonist MK-801 (0.3 or 1 mg/kg) or vehicle prior to testing on the TUNL task, or recording LFPs during the presentation of an auditory stimulus.
Results:
MK-801 impaired working memory and increased perseveration, but these behaviours were not improved by LY379268 treatment. MK-81 increased the power of ongoing gamma and high gamma (130–180 Hz) oscillations in both brain regions and regional coherence between regions, and these signatures were augmented by LY379268. However, auditory-evoked gamma oscillation deficits caused by MK-801 were not affected by LY379268 pretreatment.
Conclusions:
NMDA receptor antagonism impairs working memory in mice, but this is not reversed by stimulation of mGluR2/3. Since elevations in ongoing gamma power and regional coherence caused by MK-801 were improved by LY379268, it appears unlikely that these specific oscillatory abnormalities underlie the working memory impairment caused by NMDAr antagonism.
AdellAJimenez-SanchezLLopez-GilX, et al. (2012) Is the acute NMDA receptor hypofunction a valid model of schizophrenia?Schizophr Bull38: 9–14.
2.
AdlerCMGoldbergTEMalhotraAK, et al (1998) Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry43: 811–816.
3.
AkejuOWestoverMBPavoneKJ, et al. (2014) Effects of sevoflurane and propofol on frontal electroencephalogram power and coherence. Anesthesiology121: 990–998.
4.
AmitaiNMarkouA (2010) Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry68: 5–16.
5.
AndersonPMPinaultDO’BrienTJ, et al. (2014) Chronic administration of antipsychotics attenuates ongoing and ketamine-induced increases in cortical gamma oscillations. Int J Neuropsychopharmacol17: 1895–1904.
6.
AultmanJMMoghaddamB (2001) Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berl)153: 353–364.
7.
BattagliaGMonnJASchoeppDD (1997) In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett229: 161–164.
8.
BehrendtRP (2003) Hallucinations: synchronisation of thalamocortical gamma oscillations underconstrained by sensory input. Conscious Cogn12: 413–451.
9.
BlotKKimuraSBaiJ, et al. (2015) Modulation of hippocampus-prefrontal cortex synaptic transmission and disruption of executive cognitive functions by MK-801. Cerebral Cortex25: 1348–1361.
10.
BucciPMucciAMerlottiE, et al. (2007) Induced gamma activity and event-related coherence in schizophrenia. Clin EEG Neurosci38: 96–104.
11.
BusseyTJHolmesALyonL, et al. (2012) New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology62: 1191–1203.
12.
BuzsakiGSchomburgEW (2015) What does gamma coherence tell us about inter-regional neural communication?Nat Neurosci18: 484–489.
13.
CensitsDMRaglandJDGurRC, et al. (1997) Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: A longitudinal study. Schizophrenia research24: 289–298.
14.
ChudasamaYMuirJL (1997) A behavioural analysis of the delayed non-matching to position task: the effects of scopolamine, lesions of the fornix and of the prelimbic region on mediating behaviours by rats. Psychopharmacology (Berl)134: 73–82.
15.
CimenserAPurdonPLPierceET, et al. (2011) Tracking brain states under general anesthesia by using global coherence analysis. Proc Natl Acad Sci U S A108: 8832–8837.
16.
DajaniDRUddinLQ (2015) Demystifying cognitive flexibility: Implications for clinical and developmental neuroscience. Trends Neurosci38: 571–578.
17.
DaviesDAHurtubiseJLGrebaQ, et al. (2017) Medial prefrontal cortex and dorsomedial striatum are necessary for the trial-unique, delayed nonmatching-to-location (TUNL) task in rats: Role of NMDA receptors. Learn Mem24: 262–266.
18.
DelormeAMakeigS (2004) EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods134: 9–21.
19.
DriesenNRMcCarthyGBhagwagarZ, et al. (2013) Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry18: 1199–1204.
20.
EhrlichmanRSGandalMJMaxwellCR, et al. (2009) N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience158: 705–712.
21.
FarzanFBarrMSSunY, et al. (2012) Transcranial magnetic stimulation on the modulation of gamma oscillations in schizophrenia. Ann N Y Acad Sci1265: 25–35.
22.
FriesPReynoldsJHRorieAE, et al. (2001) Modulation of oscillatory neuronal synchronization by selective visual attention. Science291: 1560–1563.
23.
GoldJM (2004) Cognitive deficits as treatment targets in schizophrenia. Schizophr Res72: 21–28.
24.
GoldJMWaltzJAPrenticeKJ, et al. (2008) Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull34: 835–847.
25.
GreenMFKernRSBraffDL, et al. (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?Schizophr Bull26: 119–136.
26.
HakamiTJonesNCTolmachevaEA, et al. (2009) NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. PLoS One4: e6755.
27.
HeathCJBusseyTJSaksidaLM (2015) Motivational assessment of mice using the touchscreen operant testing system: effects of dopaminergic drugs. Psychopharmacology232: 4043–4057.
28.
HillSKBishopJRPalumboD, et al. (2010) Effect of second-generation antipsychotics on cognition: Current issues and future challenges. Expert Rev Neurother10: 43–57.
29.
HiyoshiTHikichiHKarasawaJ, et al. (2014) Metabotropic glutamate receptors regulate cortical gamma hyperactivities elicited by ketamine in rats. Neurosci Lett567: 30–34.
30.
HongLESummerfeltABuchananRW, et al. (2010) Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology35: 632–640.
31.
HudsonMRHannanAJO’BrienTJ, et al. (2018) High frequency neuronal oscillatory abnormalities in the phospholipase C-β1 knockout mouse model of schizophrenia. Int J Neuropsychopharmacol22: 221–231.
32.
HudsonMRRindGO’BrienTJ, et al. (2016) Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. Transl Psychiatry6: e784.
33.
HuntMJFalinskaMKasickiS (2010) Local injection of MK801 modifies oscillatory activity in the nucleus accumbens in awake rats. J Psychopharmacol24: 931–941.
34.
HuntMJKopellNJTraubRD, et al. (2017) Aberrant network activity in schizophrenia. Trends Neurosci40: 371–382.
35.
HurtubiseJLMarksWNDaviesDA, et al. (2017) MK-801-induced impairments on the trial-unique, delayed nonmatching-to-location task in rats: Effects of acute sodium nitroprusside. Psychopharmacology (Berl)234: 211–222.
36.
JensenOKaiserJLachauxJP (2007) Human gamma-frequency oscillations associated with attention and memory. Trends Neurosci30: 317–324.
37.
JonakKKrukowPKarakuła-JuchnowiczH (2016) Hyper-coherence and increased energy of gamma oscillations in patient with first onset schizophrenia and cerebral white matter damage. Curr Prob Psychiatry17: 141–148.
38.
JonesNCAndersonPRindG, et al. (2014) Effects of aberrant gamma frequency oscillations on prepulse inhibition. Int J Neuropsychopharmacol17: 1671–1681.
39.
JonesNCHudsonMForemanJ, et al. (2018) Brain-derived neurotrophic factor haploinsufficiency impairs high-frequency cortical oscillations in mice. Eur J Neurosci48: 2816–2825.
40.
JonesNCReddyMAndersonP, et al (2012a) Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power. Int J Neuropsychoph15: 657–668.
41.
JonesNCReddyMAndersonP, et al. (2012b) Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power. Int J Neuropsychopharmacol15: 657–668.
42.
KahnRSKeefeRS (2013) Schizophrenia is a cognitive illness: Time for a change in focus. JAMA Psychiatry70: 1107–1112.
43.
KimCHRombergCHvoslef-EideM, et al. (2015) Trial-unique, delayed nonmatching-to-location (TUNL) touchscreen testing for mice: Sensitivity to dorsal hippocampal dysfunction. Psychopharmacology (Berl)232: 3935–3945.
44.
KinonBJZhangLMillenBA, et al. (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol31: 349–355.
45.
KrystalJHAbi-SaabWPerryE, et al. (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl)179: 303–309.
46.
KrystalJHKarperLPSeibylJP, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry51: 199–214.
47.
KulikovaSPTolmachevaEAAndersonP, et al. (2012) Opposite effects of ketamine and deep brain stimulation on rat thalamocortical information processing. Eur J Neurosci36: 3407–3419.
48.
KumarGOlleyJStecklerT, et al. (2015) Dissociable effects of NR2A and NR2B NMDA receptor antagonism on cognitive flexibility but not pattern separation. Psychopharmacology (Berl)232: 3991–4003.
49.
KwonJSO’DonnellBFWallensteinGV, et al. (1999) Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry56: 1001–1005.
50.
LeeJHudsonMRO’BrienTJ, et al. (2017) Local NMDA receptor hypofunction evokes generalized effects on gamma and high-frequency oscillations and behavior. Neuroscience358: 124–136.
51.
LeichtGKirschVGieglingI, et al. (2010) Reduced early auditory evoked gamma-band response in patients with schizophrenia. Biol Psychiatry67: 224–231.
LorrainDSBacceiCSBristowLJ, et al. (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience117: 697–706.
54.
MenezesMMSantiniMABenvengaMJ, et al. (2013) The mGlu2/3 receptor agonists LY354740 and ly379268 differentially regulate restraint-stress-induced expression of c-Fos in rat cerebral cortex. Neurosci J2013: 736439.
55.
MoghaddamBAdamsBW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science281: 1349–1352.
56.
MonnJAValliMJMasseySM, et al. (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem42: 1027–1040.
57.
NilssonSRFejginKGastambideF, et al. (2016) Assessing the cognitive translational potential of a mouse model of the 22q11.2 microdeletion syndrome. Cereb Cortex26: 3991–4003.
58.
O’NeillMFShawG (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl)145: 237–250.
59.
PalenicekTFujakovaMBrunovskyM, et al. (2011) Electroencephalographic spectral and coherence analysis of ketamine in rats: Correlation with behavioral effects and pharmacokinetics. Neuropsychobiology63: 202–218.
60.
PalvaJMMontoSKulashekharS, et al. (2010) Neuronal synchrony reveals working memory networks and predicts individual memory capacity. Proc Natl Acad Sci U S A107: 7580–7585.
61.
PatilSTZhangLMartenyiF, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med13: 1102–1107.
62.
PinaultD (2008) N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry63: 730–735.
63.
PitsikasNMarkouA (2014) The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats. Neuropharmacology85: 27–35.
64.
SaundersJAGandalMJSiegelSJ (2012) NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. Neurobiol Dis46: 93–100.
65.
SchlumbergerCSchaferDBarberiC, et al. (2009) Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol20: 56–66.
66.
SchoeppDDJohnsonBGWrightRA, et al. (1997) LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology36: 1–11.
67.
SitskoornMMAlemanAEbischSJ, et al. (2004) Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res71: 285–295.
68.
SoRPKegelesLSMaoX, et al. (2018) Long-range gamma phase synchronization as a compensatory strategy during working memory in high-performing patients with schizophrenia. J Clin Exp Neuropsychol40: 663–681.
69.
SpellmanTRigottiMAhmariSE, et al. (2015) Hippocampal-prefrontal input supports spatial encoding in working memory. Nature522: 309–314.
70.
SpencerKM (2011) Baseline gamma power during auditory steady-state stimulation in schizophrenia. Front Hum Neurosci5: 190.
71.
SpencerKMNestorPGPerlmutterR, et al. (2004) Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci U S A101: 17288–17293.
72.
SteciukMKramMKramerGL, et al. (2000) Immobilization-induced glutamate efflux in medial prefrontal cortex: Blockade by (+)-Mk-801, a selective NMDA receptor antagonist. Stress3: 195–199.
73.
TamuraMSpellmanTJRosenAM, et al. (2017) Hippocampal-prefrontal theta-gamma coupling during performance of a spatial working memory task. Nat Commun8: 2182.
74.
VermaAMoghaddamB (1996) NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. J Neurosci16: 373–379.
75.
WieronskaJMSlawinskaAStachowiczK, et al. (2013) The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu(2)/(3) receptor agonist, LY379268, is 5-HT(1)A dependent. Behav Brain Res256: 298–304.
76.
WoolleyMLPembertonDJBateS, et al. (2008) The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl)196: 431–440.
77.
YamamotoJSuhJTakeuchiD, et al. (2014) Successful execution of working memory linked to synchronized high-frequency gamma oscillations. Cell157: 845–857.
78.
YeraganiVKCashmereDMiewaldJ, et al. (2006) Decreased coherence in higher frequency ranges (beta and gamma) between central and frontal EEG in patients with schizophrenia: A preliminary report. Psychiatry Res141: 53–60.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
